THE EFFECTS OF THE ANTIPROGESTERONE RU486 (MIFEPRISTONE) ON AN ENDOMETRIAL SECRETORY GLYCAN - AN IMMUNOCYTOCHEMICAL STUDY

被引:0
|
作者
GRAHAM, RA
LI, TC
SEIF, MW
APLIN, JD
COOKE, ID
机构
[1] UNIV MANCHESTER,ST MARYS HOSP,DEPT OBSTET & GYNAECOL,WHITWORTH PK,MANCHESTER M13 0JH,LANCS,ENGLAND
[2] UNIV SHEFFIELD,JESSOP HOSP WOMEN,DEPT OBSTET & GYNAECOL,SHEFFIELD S10 2TN,S YORKSHIRE,ENGLAND
关键词
D O I
暂无
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To examine the effects of progesterone (P) receptor blockade by RU486 (Mifepristone; Roussel-Uclaf, Paris, France) on a secretory endometrial glycan recognized by monoclonal antibody D9B1. Design: Retrospective comparison of endometrial biopsies from treated and untreated women from 2 to 8 days after the luteinizing peak (LH) peak. Setting: Infertility clinic, Jessop Hospital for Women, Sheffield. Patients: Twenty-two normal fertile women received the RU486. A control group of 44 normal fertile women were also assessed. Interventions: RU486 was administered to 22 normal women during the first half of the luteal phase and an endometrial biopsy examined 3 days later. Main Outcome Measures: Immunohistochemistry was used to assess the production and secretion of the D9B1 epitope. Results: When the drug was given 2 days after the LH peak, it prevented appearance of the epitope. When RU486 was administered 5 days after the LH peak, epitope already present in gland cells was subsequently secreted. Conclusions: These data suggest that production of the sialo-oligosaccharide is P-dependent, but secretion through established intracellular pathways is P-independent.
引用
收藏
页码:1132 / 1136
页数:5
相关论文
共 50 条
  • [1] Treatment of endometriosis with the antiprogesterone mifepristone (RU486)
    Kettel, LM
    Murphy, AA
    Morales, AJ
    Ulmann, A
    Baulieu, EE
    Yen, SSC
    [J]. FERTILITY AND STERILITY, 1996, 65 (01) : 23 - 28
  • [2] EFFECT OF MIFEPRISTONE (RU486)ON MARKERS OF ENDOMETRIAL RECEPTIVITY
    武捷
    王龙生
    程捷
    王介东
    [J]. Journal of Pharmaceutical Analysis, 2003, (01) : 89 - 92
  • [3] CLINICAL DEVELOPMENT OF AN ANTIPROGESTERONE, RU486
    CHEANG, A
    KOTTEGODA, SR
    [J]. SINGAPORE JOURNAL OF OBSTETRICS & GYNAECOLOGY, 1986, 17 (03) : 137 - 143
  • [4] Mifepristone (RU486): a review
    Mahajan, DK
    London, SN
    [J]. FERTILITY AND STERILITY, 1997, 68 (06) : 967 - 976
  • [5] Mifepristone (RU486) and abortion
    Henshaw, RC
    [J]. MEDICAL JOURNAL OF AUSTRALIA, 1997, 167 (06) : 292 - 293
  • [6] THE ANTIPROGESTERONE STEROID, RU-486 (MIFEPRISTONE)
    PERMEZEL, M
    [J]. AUSTRALIAN & NEW ZEALAND JOURNAL OF OBSTETRICS & GYNAECOLOGY, 1990, 30 (01): : 77 - 80
  • [7] Successful treatment of multiple intracranial meningiomas with the antiprogesterone receptor agent mifepristone (RU486)
    Mehdi Touat
    Giuseppe Lombardi
    Patrizia Farina
    Michel Kalamarides
    Marc Sanson
    [J]. Acta Neurochirurgica, 2014, 156 : 1831 - 1835
  • [8] Successful treatment of multiple intracranial meningiomas with the antiprogesterone receptor agent mifepristone (RU486)
    Touat, Mehdi
    Lombardi, Giuseppe
    Farina, Patrizia
    Kalamarides, Michel
    Sanson, Marc
    [J]. ACTA NEUROCHIRURGICA, 2014, 156 (10) : 1831 - 1835
  • [9] INTERRUPTION OF PRECOCIOUS GROWTH WITH THE ANTIPROGESTERONE RU486
    LESTRAT, N
    COUZINET, B
    ULMANN, A
    BAULIEU, EE
    SCHAISON, G
    [J]. ANNALES D ENDOCRINOLOGIE, 1986, 47 (04) : 261 - 261
  • [10] MIFEPRISTONE (RU486) AND EMERGENCY CONTRACEPTION
    HEWITT, I
    [J]. MEDICAL JOURNAL OF AUSTRALIA, 1995, 162 (02) : 110 - 110